ArticleiScience2026
An AIB1 isoform rewires glucocorticoid receptor signaling to promote TNBC progression.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The role of glucocorticoid receptor (GR) signaling in triple-negative breast cancer (TNBC) progression remains poorly defined. Here, we describe a GR-dependent mechanism driving TNBC invasion, mediated by the presence of a subpopulation of cancer cells that express an N-terminal truncated splice isoform of the nuclear receptor coactivator AIB1. Invasion was driven through direct contact of this subpopulation with neighboring cancer cells, and suppressed by GR antagonists or depletion of GR. Crosstalk between the AIB1 isoform-expressing cells and full-length AIB1-expressing cells triggered enhanced GR activation, GR signaling, and distinct patterns of AIB1 genomic engagement. Notably, GR signaling selectively activated pathways driven by Myc in the AIB1 isoform-expressing population, and the reduction of Myc reduced invasion. These findings identify the emergence of an AIB1 isoform-expressing subpopulation as a key mechanism driving progression in TNBC and suggest sensitivity to GR-targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.